---

---

t-cell   crawled time : 12:20   

save search

---

Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
Published: 2023-06-13 (Crawled : 12:20) - globenewswire.com
PBLA | $0.4895 -6.31% 66K |

Professional, Scientific, and T...

| -93.54% | O: 13.23% H: 22.83% C: -16.44%
metabolic cell research car-t agreement therapy

---

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
Published: 2023-06-04 (Crawled : 12:20) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K |

Health Technology

| Email alert Add to watchlist
trilaciclib tumor

---

Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
Published: 2023-03-31 (Crawled : 12:20) - globenewswire.com
IMMX | $2.21 0.0% 64K |

| 27.33% | O: 2.33% H: 6.24% C: 3.41%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -3.6% | O: 0.23% H: 0.91% C: 0.79%
nxc-201 drug approved food biopharma

---

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K |

| 165.13% | O: 7.69% H: 0.0% C: -9.52%
immunotherapy car-t therapeutics therapy study

---

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy
Published: 2022-10-24 (Crawled : 12:20) - biospace.com/
IMUN | $0.093 214.52% 1.8K |

Manufacturing

| Email alert Add to watchlist
research conference preclinical immunotherapy immunology therapeutics cancer platform

---

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2022-10-05 (Crawled : 12:20) - globenewswire.com
LYEL | $2.24 -3.86% -4.02% 1.1M |

Professional, Scientific, and T...

| -71.98% | O: -0.88% H: 2.15% C: 0.51%
preclinical immunotherapy meeting growing t-cell cancer

---

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Published: 2022-09-26 (Crawled : 12:20) - globenewswire.com
LVTX | $2.72 -3.89% -4.04% 130K |

| 12.92% | O: 129.58% H: 2.9% C: -13.97%
SGEN | $228.74 0.1% 20M |

Health Technology

| 64.32% | O: 0.09% H: 0.45% C: -2.91%
lava-1223 preclinical license therapeutics agreement

---

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma
Published: 2022-07-12 (Crawled : 12:20) - prnewswire.com
CTXR | $0.7477 -7.18% -7.73% 1.7M |

Health Technology

| -17.0% | O: 2.7% H: 0.0% C: -2.81%
treatment fda meeting t-cell

---

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme DiseaseT-Detect Lyme
Published: 2022-06-15 (Crawled : 12:20) - biospace.com/
ADPT | $2.41 3.21% 3.11% 2.3M |

Commercial Services

| -62.03% | O: 4.11% H: 11.78% C: 8.66%
test t-cell

---

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
Published: 2022-05-16 (Crawled : 12:20) - globenewswire.com
CLLS | $2.47 0.4% 12K |

Health Technology

| -16.39% | O: 4.59% H: 0.63% C: -1.57%
ALLO | $3.48 0.58% 0.57% 2M |

Health Technology

| -52.34% | O: -1.92% H: 3.5% C: -0.84%
research t-cell

---

Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Published: 2022-05-11 (Crawled : 12:20) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 148.8% | O: -3.03% H: 0.0% C: 0.0%
biopharma disease

---

Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
Published: 2022-04-14 (Crawled : 12:20) - globenewswire.com
ALLO | $3.48 0.58% 0.57% 2M |

Health Technology

| -60.39% | O: -0.91% H: 0.14% C: -4.95%
therapeutics designation

---

Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 9.77% | O: 1.14% H: 0.0% C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---